|
|
|
|
| LEADER |
03090nam a2200565 4500 |
| 001 |
ocn866839740 |
| 003 |
OCoLC |
| 005 |
20170124072333.5 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
131227s2014 gw o 001 0 eng d |
| 040 |
|
|
|a IDEBK
|b eng
|e pn
|c IDEBK
|d EBLCP
|d DG1
|d YDXCP
|d RECBK
|d OCLCF
|d OCLCQ
|d DEBSZ
|d DEBBG
|d OCLCQ
|d GrThAP
|
| 020 |
|
|
|a 9783527675272
|q (electronic bk.)
|
| 020 |
|
|
|a 3527675272
|q (electronic bk.)
|
| 020 |
|
|
|a 1306256178
|q (electronic bk.)
|
| 020 |
|
|
|a 9781306256179
|q (electronic bk.)
|
| 020 |
|
|
|a 9783527675296
|
| 020 |
|
|
|a 3527675299
|
| 029 |
1 |
|
|a DEBBG
|b BV043396444
|
| 029 |
1 |
|
|a DEBSZ
|b 431590923
|
| 029 |
1 |
|
|a GBVCP
|b 790211157
|
| 029 |
1 |
|
|a NZ1
|b 15495744
|
| 035 |
|
|
|a (OCoLC)866839740
|
| 037 |
|
|
|a 556868
|b MIL
|
| 050 |
|
4 |
|a RS431.P38
|
| 050 |
|
4 |
|a RS420
|b .C384 2013
|
| 082 |
0 |
4 |
|a 615.3
|2 23
|
| 082 |
0 |
4 |
|a 613.5
|
| 049 |
|
|
|a MAIN
|
| 245 |
0 |
0 |
|a Therapeutic Fc Fusion Proteins /
|c edited by Steven M. Chamow [and others].
|
| 264 |
|
1 |
|a Weinheim :
|b Wiley-Blackwell,
|c [2014]
|
| 264 |
|
4 |
|c ©2014
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 505 |
0 |
|
|a Introduction: Antibody Structure and Function / Arvind Rajpal, Pavel Strop, Yik Andy Yeung, Javier Chaparro-Riggers, Jaume Pons -- Methods of Production for Fc-Fusion Proteins. Fc-Fusion Protein Expression Technology / Jody D Berry, Catherine Yang, Janean Fisher, Ella Mendoza, Shanique Young, Dwayne Stupack -- Cell Culture-Based Production / Yao-Ming Huang, Rashmi Kshirsagar, Barbara Woppmann, Thomas Ryll -- Downstream Processing of Fc-Fusion Proteins / Abhinav A Shukla, Uwe Gottschalk -- Formulation, Drug Product, and Delivery: Considerations for Fc-Fusion Proteins / Wenjin Cao, Deirdre Murphy Piedmonte, Margaret Speed Ricci, Ping Y Yeh -- Quality by Design Applied to a Fc-Fusion Protein: A Case Study / Alex Eon-Duval, Ralf Gleixner, Pascal Valax, Miroslav Soos, Benjamin Neunstoecklin, Massimo Morbidelli, Hervé Broly -- Analytical Methods Used to Characterize Fc-Fusion Proteins / Esohe Idusogie, Michael Mulkerrin -- Case Studies of Therapeutic Fc-Fusion Proteins. Introduction to Therapeutic Fc-Fusion Proteins / Jody D Berry -- Alefacept / Deborah A Farson -- Etanercept / Johanna Grossman, Steven M Chamow -- Abatacept and Belatacept / Robert J Peach -- Aflibercept / Angela L Linderholm, Steven M Chamow -- Recombinant Factor VIII- and Factor IX-Fc Fusions / Robert T Peters, Judy R Berlfein.
|
| 500 |
|
|
|a Includes index.
|
| 588 |
0 |
|
|a Print version record.
|
| 650 |
|
0 |
|a Peptide drugs.
|
| 650 |
|
0 |
|a Proteins.
|
| 650 |
|
0 |
|a Proteins
|x Synthesis.
|
| 650 |
|
7 |
|a Peptide drugs.
|2 fast
|0 (OCoLC)fst01057556
|
| 650 |
|
7 |
|a Proteins.
|2 fast
|0 (OCoLC)fst01079711
|
| 650 |
|
7 |
|a Proteins
|x Synthesis.
|2 fast
|0 (OCoLC)fst01079764
|
| 655 |
|
4 |
|a Electronic books.
|
| 700 |
1 |
|
|a Chamow, Steven Mark.
|
| 776 |
0 |
8 |
|i Print version:
|z 9781306256179
|
| 856 |
4 |
0 |
|u https://doi.org/10.1002/9783527675272
|z Full Text via HEAL-Link
|
| 994 |
|
|
|a 92
|b DG1
|
